{
    "title": "112_hr6584",
    "content": "The Act titled \"Verifying Authority and Legality In Drug Compounding Act of 2012\" amends Section 503A of the Federal Food, Drug, and Cosmetic Act to regulate pharmacy compounding. The Act \"Verifying Authority and Legality In Drug Compounding Act of 2012\" amends Section 503A of the Federal Food, Drug, and Cosmetic Act to regulate pharmacy compounding. Sections 501(a)(2)(B) and 505 exemptions apply to compounded drug products for identified patients with valid prescriptions, compounded by licensed pharmacists or physicians using ingredients meeting USP standards. The Act \"Verifying Authority and Legality In Drug Compounding Act of 2012\" amends Section 503A of the Federal Food, Drug, and Cosmetic Act to regulate pharmacy compounding. Any bulk substance used for compounding must be manufactured by a registered establishment under section 510. The Act \"Verifying Authority and Legality In Drug Compounding Act of 2012\" amends Section 503A of the Federal Food, Drug, and Cosmetic Act to regulate pharmacy compounding. Compounded drug products must comply with US Pharmacopoeia standards and not be on a list of prohibited products. The Act \"Verifying Authority and Legality In Drug Compounding Act of 2012\" amends Section 503A of the Federal Food, Drug, and Cosmetic Act to regulate pharmacy compounding. Compounded drug products must comply with US Pharmacopoeia standards and not be on a list of prohibited products, which includes those that may cause adverse effects on safety or effectiveness, or have been withdrawn from the market for safety or efficacy reasons. The Secretary is required to publish and update a list of approved compounded drug products annually, which will be available on the FDA website. The updated list will also be transmitted to state regulatory agencies. The Secretary may waive the requirement for individually identified patients for certain drug products if necessary to address a drug shortage or protect public health. The waiver duration is limited to 1 year, with possible extensions for continued shortage mitigation. The Secretary may waive the requirement for individually identified patients for certain drug products to address a drug shortage or protect public health. States are prohibited from granting waivers under this subsection. Pharmacies or pharmacists can apply for a waiver if they meet specified requirements and agree to comply with conditions. The Secretary may waive the requirement for individually identified patients for certain drug products to address a drug shortage or protect public health. Pharmacies or pharmacists can apply for a waiver if they meet specified requirements and agree to comply with conditions, excluding ineligible pharmacies like those compounding drug products within a hospital system. The Secretary may authorize states to grant waivers to pharmacies and pharmacists for compounding drug products in limited quantities before receiving a valid prescription for patients in the same state. The Secretary may authorize states to grant waivers for compounding drug products in limited quantities before receiving a valid prescription, ensuring compliance with requirements and including necessary information and assurances as determined by the Secretary. The Secretary may authorize states to grant waivers for compounding drug products sold or dispensed within the state, with limitations on types of pharmacies and pharmacists specified. Applications and requirements for waivers are specified by the Secretary in regulations. The information required for a waiver application includes circumstances supporting approval, criteria for evaluation, conditions of operation, and limitations on activities. The Secretary may waive the requirement for copies of commercially available drugs sold or dispensed by pharmacies or pharmacists, specifying limitations and duration of the waiver. Specific requirements are tailored to each type of pharmacy and pharmacist. The Secretary may waive the requirement of subsection (a)(7) for compounding drugs to protect public health. The waiver duration is limited to 1 year, with possible extensions for public health reasons. States are prohibited from granting waivers. Pharmacies compounding drugs under waivers are subject to inspections for compliance. The Secretary can cancel waivers and publish notice accordingly. The Secretary can cancel a waiver under subsections (c), (d), or (e) with a 30-day notice, except for cases impacting public health or safety. Drug labeling for compounded products must include a statement about lack of FDA approval and reporting adverse reactions. Pharmacists and physicians must report adverse events. Pharmacists and physicians compounding drug products must report adverse events and information related to risks promptly to the Secretary. The Secretary shall promulgate regulations for reporting adverse events and risks related to compounded drug products, including specifying pharmacies and pharmacists, waiver criteria, required information, inspection requirements, and definitions. The term 'compounding' excludes acts like mixing or reconstituting according to approved labeling. Misbranding of compounded drug products is defined as lacking required labeling statements. The FDA requires labeling statements for compounded drug products, with regulations to be finalized within a year of the enactment of the Act. The amendments will take effect one year after the Act's enactment. SEC. 3. Registration and inspection of manufacturers compounding drug products. The amendment to the Federal Food, Drug, and Cosmetic Act requires pharmacies compounding drugs to be inspected if they are deemed to be manufacturing drugs. The extent of manufacturing is determined by factors such as selling drugs across state lines and quantity sold. The Secretary of Health and Human Services will establish regulations within a year for pharmacies compounding drugs to be inspected if they are considered to be manufacturing drugs. The extent of manufacturing is determined by factors like selling drugs across state lines and quantity sold. The amendment will take effect one year after the enactment of the Act."
}